Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Liver Function in Older Patients With Unresectable Hepatocellular Carcinoma After Administration of Lenvatinib.
Sasaki R, Fukushima M, Haraguchi M, Miuma S, Miyaaki H, Hidaka M, Eguchi S, Matsuo S, Matsuzaki T, Hashimoto S, Ohba K, Kugiyama Y, Yatsuhashi H, Shibata H, Motoyoshi Y, Shigeno M, Iwatsu S, Kato Y, Kinoshita N, Nakao K. Sasaki R, et al. Among authors: shigeno m. Anticancer Res. 2021 Apr;41(4):2025-2032. doi: 10.21873/anticanres.14970. Anticancer Res. 2021. PMID: 33813409
Geranylgeraniol, an intermediate product in mevalonate pathway, induces apoptotic cell death in human hepatoma cells: death receptor-independent activation of caspase-8 with down-regulation of Bcl-xL expression.
Takeda Y, Nakao K, Nakata K, Kawakami A, Ida H, Ichikawa T, Shigeno M, Kajiya Y, Hamasaki K, Kato Y, Eguchi K. Takeda Y, et al. Among authors: shigeno m. Jpn J Cancer Res. 2001 Sep;92(9):918-25. doi: 10.1111/j.1349-7006.2001.tb01181.x. Jpn J Cancer Res. 2001. PMID: 11572758 Free PMC article.
Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.
Mashiba T, Joko K, Kurosaki M, Ochi H, Osaki Y, Kojima Y, Nakata R, Goto T, Takehiro A, Kimura H, Mitsuda A, Kawanami C, Uchida Y, Ogawa C, Kusakabe A, Narita R, Ide Y, Abe T, Tsuji K, Kitamura T, Okada K, Sohda T, Shigeno M, Satou T, Izumi N. Mashiba T, et al. Among authors: shigeno m. PLoS One. 2018 Apr 16;13(4):e0194704. doi: 10.1371/journal.pone.0194704. eCollection 2018. PLoS One. 2018. PMID: 29659591 Free PMC article.
Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings.
Sasaki R, Fukushima M, Haraguchi M, Miuma S, Miyaaki H, Hidaka M, Eguchi S, Matsuo S, Tajima K, Matsuzaki T, Hashimoto S, Ooba K, Kugiyama Y, Yatsuhashi H, Motoyoshi Y, Shigeno M, Kinoshita N, Nakao K. Sasaki R, et al. Among authors: shigeno m. Cancers (Basel). 2019 Nov 10;11(11):1769. doi: 10.3390/cancers11111769. Cancers (Basel). 2019. PMID: 31717674 Free PMC article.
The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study.
Tsuchiya K, Kurosaki M, Sakamoto A, Marusawa H, Kojima Y, Hasebe C, Arai H, Joko K, Kondo M, Tsuji K, Sohda T, Kimura H, Ogawa C, Uchida Y, Wada S, Kobashi H, Furuta K, Shigeno M, Kusakabe A, Akahane T, Narita R, Yoshida H, Mitsuda A, Ide Y, Matsushita T, Izumi N, On Behalf Of Japanese Red Cross Liver Study Group. Tsuchiya K, et al. Among authors: shigeno m. Cancers (Basel). 2021 May 26;13(11):2608. doi: 10.3390/cancers13112608. Cancers (Basel). 2021. PMID: 34073396 Free PMC article.
94 results